Stanford inventors have developed a cell-free method for carbon-negative biosynthetic production of commodity biochemicals by using hydrogen gas as a source of reducing equivalents.
Stanford researchers in the Swartz lab have proposed a method to synthesize metabolic cofactors from inexpensive substrates for protein synthesis and commodity production applications.
Stanford researchers in the Swartz lab have developed a method for improving the productivity of biosynthetic processes via enzymatic detoxification of aberrant forms of NAD(P)H.
Stanford inventors have developed the CasKAS method for profiling CRISPR off-targets using single-stranded DNA (ssDNA) mapping. Binding of CRISPR protein to DNA generates ssDNA structures, which can be a sensitive biochemical signal of CRISPR occupancy.
IPEX syndrome is a severe autoimmune disease with limited treatment options caused by mutations in the forkhead box protein 3 (FOXP3) gene, which plays a critical role in immune regulation.
Researchers at Stanford have developed gene editing methods for modifying hematopoietic stem and progenitor cells (HSPCs) to express truncated forms of the erythropoietin receptor (tEPOR).
Polycythemia vera is a rare blood cancer characterized by the hyperproliferation of red blood cells, leading to coagulation events like strokes and heart attacks.
Ultrasound technology is a safe, high-resolution, and cost-efficient tool for imaging. Other modalities, such as MRI or CT, may require the use of anesthesia. This makes it difficult to image pediatric patients and patients sensitive to anesthesia.
Stanford inventors have developed a method for collagen compression along with a polymer mesh as a mechanical support to produce collagen-based composite grafts.
Stanford inventors have developed a method of using CRISPR/Cas9 or similar gene editing technologies to genetically edit an individual's own myeloid cells for specific gene targets, which are critical to wound repair, and applying these edited cells in a hydrogel to promote ra
Researchers in Prof. David Myung's laboratory have developed a bio-compatible, crosslinking gel that can be used for in situ repair of damaged cornea or as a three-dimensional scaffold for keratocyte-keratinocyte tissue culture.